Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 14.68%3.09B | 183.19%198M | -8.58%-1.49B | 30.98%1.5B | -8.81%2.88B | -21.80%2.69B | -30.77%-238M | -37.91%-1.38B | -29.61%1.15B | 5.55%3.16B |
Net income from continuing operations | 77.91%1.22B | 121.32%301M | 124.26%684M | -3.10%375M | 2.86%-136M | 100.58%688M | -22.29%136M | -35.92%305M | 309.19%387M | -13.82%-140M |
Operating gains losses | -381.25%-154M | 93.02%-12M | -187.00%-194M | 54.84%-28M | 480.95%80M | -106.37%-32M | -191.49%-172M | 190.65%223M | -111.42%-62M | -223.53%-21M |
Depreciation and amortization | 3.84%838M | 1.92%212M | 1.44%211M | 3.02%205M | 9.38%210M | 1.89%807M | 4.52%208M | 4.52%208M | 1.02%199M | -2.54%192M |
Deferred tax | 19.35%74M | -38.46%8M | -59.09%27M | 92.50%77M | 33.33%-38M | -11.43%62M | 136.11%13M | -65.08%66M | 122.22%40M | 43.56%-57M |
Other non cash items | 43.64%79M | -52.38%10M | 416.67%31M | 100.00%28M | -28.57%10M | 223.53%55M | 105.53%21M | -98.56%6M | 166.67%14M | 600.00%14M |
Change In working capital | 54.61%419M | 19.63%-528M | 6.46%-2.43B | 58.01%730M | -13.60%2.65B | -78.51%271M | -55.69%-657M | -19.27%-2.6B | -51.57%462M | 5.40%3.07B |
-Change in receivables | 36.98%-467M | 1,559.46%540M | 149.30%354M | 0.77%-387M | -113.60%-974M | 11.58%-741M | 58.89%-37M | -17.92%142M | 12.36%-390M | 4.20%-456M |
-Change in prepaid assets | -31.63%67M | 56.36%86M | -15.26%161M | -106.16%-9M | 41.64%-171M | 78.18%98M | 129.17%55M | -47.37%190M | 461.54%146M | 17.70%-293M |
-Change in payables and accrued expense | -104.85%-21M | -709.38%-195M | -346.25%-394M | 30.00%442M | 227.27%126M | -23.90%433M | 158.18%32M | 216.79%160M | -34.87%340M | -141.42%-99M |
-Change in other working capital | 74.64%840M | -35.64%-959M | 17.43%-2.55B | 86.89%684M | -6.29%3.67B | -67.39%481M | -134.88%-707M | -19.98%-3.09B | -56.99%366M | 11.76%3.91B |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 14.68%3.09B | 183.19%198M | -8.58%-1.49B | 30.98%1.5B | -8.81%2.88B | -21.80%2.69B | -30.77%-238M | -37.91%-1.38B | -29.61%1.15B | 5.55%3.16B |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -57.75%-1.26B | -118.79%-361M | -83.00%-452M | -8.29%-209M | -23.08%-240M | -37.93%-800M | -150.00%-165M | 7.14%-247M | 26.05%-193M | -1,600.00%-195M |
Capital expenditure reported | 10.64%-756M | -7.91%-191M | 8.92%-194M | 13.00%-194M | 24.03%-177M | -27.79%-846M | 0.00%-177M | -25.29%-213M | -40.25%-223M | -49.36%-233M |
Net investment purchase and sale | -2,342.86%-471M | -289.29%-109M | -1,344.44%-336M | --0 | -620.00%-26M | -85.52%21M | -660.00%-28M | --27M | 128.33%17M | -97.50%5M |
Net other investing changes | -240.00%-35M | -252.50%-61M | 227.87%78M | -215.38%-15M | -212.12%-37M | 139.68%25M | -62.26%40M | 36.46%-61M | 130.95%13M | 206.45%33M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -57.75%-1.26B | -118.79%-361M | -83.00%-452M | -8.29%-209M | -23.08%-240M | -37.93%-800M | -150.00%-165M | 7.14%-247M | 26.05%-193M | -1,600.00%-195M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 16.75%-1.75B | 68.81%-155M | 24.10%-441M | 10.84%-518M | -44.39%-631M | 20.12%-2.1B | -31.13%-497M | -4.12%-581M | 43.26%-581M | 34.09%-437M |
Net issuance payments of debt | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net common stock issuance | 13.94%-1.84B | 57.69%-198M | 22.73%-469M | 10.79%-529M | -37.10%-643M | -252.06%-2.14B | -27.87%-468M | -252.91%-607M | -2,595.45%-593M | -897.87%-469M |
Proceeds from stock option exercised by employees | 14.85%116M | -18.75%39M | 123.08%29M | 45.45%16M | 10.34%32M | -22.90%101M | 700.00%48M | 18.18%13M | -15.38%11M | -71.29%29M |
Net other financing activities | 63.33%-22M | 105.19%4M | -107.69%-1M | -600.00%-5M | -766.67%-20M | -757.14%-60M | -305.26%-77M | -35.00%13M | 106.67%1M | -57.14%3M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 16.75%-1.75B | 68.81%-155M | 24.10%-441M | 10.84%-518M | -44.39%-631M | 20.12%-2.1B | -31.13%-497M | -4.12%-581M | 43.26%-581M | 34.09%-437M |
Net cash flow | ||||||||||
Beginning cash position | -3.25%5.66B | -6.87%6.05B | -4.52%8.36B | -9.12%7.62B | -3.25%5.66B | 0.79%5.85B | 1.98%6.49B | 5.21%8.76B | 3.10%8.39B | 0.79%5.85B |
Current changes in cash | 137.86%78M | 64.67%-318M | -8.31%-2.39B | 108.06%774M | -20.48%2.01B | -187.29%-206M | -43.54%-900M | -20.98%-2.2B | 8.45%372M | 7.86%2.53B |
Effect of exchange rate changes | -1,131.25%-165M | -323.19%-154M | 211.11%70M | -3,300.00%-34M | -527.27%-47M | 108.42%16M | -38.39%69M | 54.01%-63M | 99.35%-1M | 200.00%11M |
End cash Position | -1.54%5.57B | -1.54%5.57B | -6.87%6.05B | -4.52%8.36B | -9.12%7.62B | -3.25%5.66B | -3.25%5.66B | 1.98%6.49B | 5.21%8.76B | 3.10%8.39B |
Free cash flow | 26.30%2.33B | 101.69%7M | -6.23%-1.69B | 41.60%1.31B | -7.59%2.7B | -33.62%1.84B | -15.60%-415M | -36.08%-1.59B | -37.17%923M | 3.14%2.92B |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |